S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NASDAQ:HROW

Harrow Health (HROW) Stock Price, News & Analysis

$10.45
-0.40 (-3.69%)
(As of 04/19/2024 ET)
Today's Range
$10.28
$10.88
50-Day Range
$10.18
$13.51
52-Week Range
$7.60
$28.25
Volume
681,038 shs
Average Volume
439,065 shs
Market Capitalization
$369.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.13

Harrow Health MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
168.2% Upside
$28.13 Price Target
Short Interest
Bearish
17.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.05mentions of Harrow Health in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$1.23 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.39) to $0.69 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.43 out of 5 stars

Medical Sector

492nd out of 918 stocks

Pharmaceutical Preparations Industry

221st out of 417 stocks

HROW stock logo

About Harrow Health Stock (NASDAQ:HROW)

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

HROW Stock Price History

HROW Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Harrow Health (NASDAQ:HROW) Coverage Initiated at Craig Hallum
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Why Is Harrow (HROW) Stock Up 5% Today?
Earnings Preview: Harrow Health
Harrow (HROW) Fell on Lowering the Guidance
HROWM Harrow Health, Inc. NT CAL 27
Harrow to Present at Two Investor Conferences in November
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/19/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.13
High Stock Price Target
$34.40
Low Stock Price Target
$24.00
Potential Upside/Downside
+159.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-24,410,000.00
Pretax Margin
-18.21%

Debt

Sales & Book Value

Annual Sales
$130.19 million
Book Value
$2.01 per share

Miscellaneous

Free Float
30,554,000
Market Cap
$383.66 million
Optionable
Optionable
Beta
0.48
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer

HROW Stock Analysis - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price target for 2024?

2 brokerages have issued 12-month target prices for Harrow Health's shares. Their HROW share price targets range from $24.00 to $34.40. On average, they predict the company's stock price to reach $28.13 in the next twelve months. This suggests a possible upside of 168.2% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2024?

Harrow Health's stock was trading at $11.20 at the beginning of 2024. Since then, HROW shares have decreased by 6.3% and is now trading at $10.49.
View the best growth stocks for 2024 here
.

Are investors shorting Harrow Health?

Harrow Health saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 6,120,000 shares, an increase of 11.3% from the March 15th total of 5,500,000 shares. Based on an average daily volume of 427,600 shares, the short-interest ratio is presently 14.3 days.
View Harrow Health's Short Interest
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.27) earnings per share (EPS) for the quarter. The company had revenue of $36.36 million for the quarter, compared to the consensus estimate of $37.65 million. Harrow Health had a negative trailing twelve-month return on equity of 29.48% and a negative net margin of 18.75%.

What ETF holds Harrow Health's stock?

Jacob Forward ETF holds 10,538 shares of HROW stock, representing 4.41% of its portfolio.

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its FY 2024 earnings guidance on Friday, March, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $188.7 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Wasatch Advisors LP (1.10%) and Woodmont Investment Counsel LLC (0.60%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HROW) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners